Top Markets
Coin of the day
Aeolus Pharmaceuticals, Inc. Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals, Inc.

AOLS
Rank in Stocks #41596
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the... Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the development of innovative therapeutic compounds. Operating within the United States, the company's research pipeline addresses a diverse range of critical medical challenges, including biodefense, fibrotic conditions, oncology, infectious diseases, and central nervous system disorders. A core focus involves a distinct class of catalytic antioxidant compounds, which are being advanced as essential medical countermeasures against threats from nuclear, radiological, and chemical weapons, in addition to therapies for respiratory, neurological, and oncological ailments. Their flagship product candidate, AEOL 10150, has successfully navigated two Phase I clinical trials. This compound is being developed to combat the pulmonary complications associated with acute radiation syndrome, and also serves as a crucial protective agent against exposure to chemical vesicants and nerve agents. Further expanding its pipeline, Aeolus is also pursuing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, alongside AEOL 20415, designed to address various infectious diseases. Established in 1994, Aeolus Pharmaceuticals is headquartered in Mission Viejo, California.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$15.21K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Aeolus Pharmaceuticals, Inc. (AOLS)

Category

P/B ratio for Aeolus Pharmaceuticals, Inc. (AOLS)
P/B ratio as of 2026 TTM: 0
According to Aeolus Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Aeolus Pharmaceuticals, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors